Mechanism
AOD-9604 is the C-terminal fragment of human growth hormone — the short tail (residues 176–191) isolated in the hope of capturing hGH’s fat-burning effect while leaving its growth-promoting machinery behind. The theory is elegant; whether it translates to meaningful human fat loss is the whole question.
| Mechanism | Detail |
|---|---|
| Lipolytic fragment of hGH | Reproduces the fat-mobilizing region of growth hormone without the full molecule’s receptor-binding domains — the design intent was “fat-loss signal, minus the hormone.” |
| Stimulates lipolysis | In fat cells it is proposed to trigger breakdown of stored triglycerides, releasing fatty acids for energy. |
| Promotes fat oxidation | Reported to increase the rate at which fat is burned rather than re-stored — clearer in rodent and cell models than in humans. |
| Spares the IGF-1 axis | A repeatedly cited selling point: across human trials it did not raise serum IGF-1, did not impair glucose tolerance, and did not promote tissue growth the way full hGH can. |
Evidence Summary
AOD-9604 is unusual: it has more genuine human trial data than most research peptides, and that data is mostly a cautionary tale. The marketing leans on early proof-of-concept signals; the larger, better-powered trials did not deliver.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Fat oxidation (preclinical) | Increased lipolysis in models | Animal / in vitro | The mechanistic story is real in models — the source of the reputation. |
| Early proof-of-concept | ~1.8 kg edge vs placebo (small) | Human (small) | Enough to justify further trials, not enough to call it effective. |
| Pivotal weight-loss trial | Did NOT beat placebo (534 pts, 24 wk) | Human (Phase 2b) | The decisive study. The obesity program was abandoned; results never peer-published. |
| Metabolic safety markers | No IGF-1 or glucose impairment | Human (pooled) | The one consistently favorable finding — it behaved as intended on safety. |
| Osteoarthritis / cartilage | Reduced cartilage degeneration | Animal | A newer direction; no human Phase 3 OA trial exists. |
| Human clinical trials | Largest failed its weight endpoint | Human | Despite years of study, no clinically meaningful weight loss demonstrated in humans. |
Divergence — What This Means
A clean safety story wrapped around a failed efficacy claim.
AOD-9604 is sold as a clean, side-effect-free “fat-loss peptide,” and the safety half of that pitch is largely supported — it is well tolerated and does not disturb IGF-1 or blood sugar.
The divergence is on efficacy. Marketing traces back to early proof-of-concept signals, while the largest human trial (534 patients, 24 weeks) simply failed to beat placebo on weight loss. Divergence is moderate: the compound is real and the safety story holds, but the headline claim — meaningful fat loss in people — is not backed by the pivotal data.
The divergence is on efficacy. Marketing traces back to early proof-of-concept signals, while the largest human trial (534 patients, 24 weeks) simply failed to beat placebo on weight loss. Divergence is moderate: the compound is real and the safety story holds, but the headline claim — meaningful fat loss in people — is not backed by the pivotal data.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Common research range
300–500 mcg
per day, subcutaneous, reported protocols
Trial oral dose
~1 mg / day
the oral dose used in human obesity trials
Frequency
Once daily
often a morning/fasted window in anecdote
Route
Subcutaneous
most research use; oral was trial-specific
These figures describe what appears in trials and community protocols — not a recommendation. There is no established therapeutic dose (AOD-9604 is not approved), and the studied doses did not produce reliable weight loss. For research context only.
Safety Profile
On safety, AOD-9604 is one of the better-characterized research peptides — and the news is relatively reassuring. Across pooled placebo-controlled trials its adverse-event profile was largely indistinguishable from placebo. The caveats are about long-term and non-approved use.
Animal / preclinical — signals observed
Mild, transient injection-site redness
Overall adverse-event rate comparable to placebo in pooled trials
No serum IGF-1 elevation and no glucose-tolerance impairment in trials
No anti-drug antibody formation reported
What is not known (human)
Long-term safety beyond the months-long trial windows
Effects of chronic use at the higher doses seen in community protocols
Safety and content of unregulated research-market product
Intra-articular (joint injection) safety in humans — studied only in animals
Interactions with other peptides, GLP-1 agonists, or metabolic drugs
A clean trial safety profile is not a guarantee for gray-market material used outside a study setting. This is not medical advice.
Regulatory Status — Updated July 2026
Flagged, but not yet reviewed
AOD-9604 was not part of the July 2026 PCAC 503A review. It has been named among peptides flagged for reconsideration in 2026, but it was not formally reviewed or voted on — its status remains pending. It is currently sold research-use-only and is not FDA-approved for any indication. Track current status →
Where to Source
Source research-grade AOD-9604
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source AOD-9604.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
Largely no. Early small studies hinted at a modest edge over placebo (~1.8 kg), but the pivotal Phase 2b trial — 534 patients over 24 weeks — did not separate from placebo at any dose. The obesity program was abandoned. Despite the marketing, controlled human evidence does not support meaningful fat loss.
No. It was not included in the July 2026 PCAC 503A review and was not formally reviewed or voted on. It has been flagged for possible reconsideration, but its status is pending, not decided.
AOD-9604 received self-affirmed Generally Recognized as Safe (GRAS) status in some food/supplement contexts. GRAS is a safety-of-ingredient designation — it is not FDA drug approval and says nothing about whether the peptide works for weight loss.
A separate, newer research direction from fat loss. Animal studies (e.g., intra-articular AOD-9604 with hyaluronic acid in rabbits) showed reduced cartilage degeneration. There is no Phase 3 human osteoarthritis trial, so this remains exploratory.
Compare AOD-9604